FierceBiotech

OGX-011 Shows Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study

for OGX-011 in combination with docetaxel and prednisone and a 16.9 months overall survival for docetaxel and prednisone alone. Achievement of survival benefit milestone results in release of ...
Newswire

OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer

Company Reaffirms Commitment to Addressing Treatment Resistance in Genitourinary (GU) Cancers with Fourth Phase 2 GU trial in OGX-427 ORCA Program BOTHELL, Wash. and VANCOUVER, British Columbia, Feb.
ascopubs.org

A phase I/II study of OGX-011 and a gemcitabine (GEM)/platinum regimen as first-line therapy in 85 patients with advanced non-small cell lung cancer

Phase II randomized trial of docetaxel plus cetuximab or bortezomib in patients with advanced NSCLC and performance status (PS) 2—CALGB 30402 No significant financial relationships to disclose. This ...